Navigation Links
HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
Date:6/16/2009

asts, the two major cell types found in human skin. Using a unique delivery system, the cells are sprayed onto the wound surface in a self-polymerizing protein mesh intended to help the cells to adhere to the tissue.

Previous research strongly suggests that wound healing is accelerated by the application of living cells, particularly when both keratinocytes and fibroblasts are present together. By allowing the cells to be in contact with each other following spraying onto the wound surface, it is thought that growth promoting and healing signals will be generated that can support healing of the wound by the patient's own cells.

Typically caused by impaired microcirculation secondary to venous hypertension, venous leg ulcers are increasingly common, are costly, and are often a cause of prolonged suffering for patients. Characterized as difficult to heal, many such ulcers develop into chronic, nonresponsive wounds despite application of standard treatments.

"Making an innovative, effective treatment available is a strategy that can help such high risk wounds and provide tremendous benefits to both patients and society," said Dr. Slade. "Based on an estimated 2.5 million venous leg ulcers in the United States alone and actual direct treatment costs reported to be over $9,000 per patient, the current annual cost of treating these wounds is likely in the many billions of dollars."

"We are excited to be working with HEALTHPOINT on this important study," said Dr. Reyzelman. "We're aided greatly by HEALTHPOINT's investment in cutting edge technology to support this trial, including new laser-equipped digital cameras that can measure wound size at each clinic visit."

"We believe development of our HP802-247 product will result in helping millions of patients worldwide who suffer from these ulcers," said Travis E. Baugh, President of HEALTHPOINT. "The novel format of this cell-based ther
'/>"/>

SOURCE HEALTHPOINT, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
2. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
3. MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series
4. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
5. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
6. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
7. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
8. Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers
9. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
10. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
11. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Mass. , July 29, 2014  Instrumentation Laboratory (IL) ... including a new corporate logo. This is part of a ... Founded in Boston, MA , ... family of companies since 1992.  Other companies in the group ... Biokit and Systelab ( Barcelona, Spain ).  Like ...
(Date:7/29/2014)... LINCOLNSHIRE, Ill. , July 29, 2014  Sysmex ... equipment and information systems technology, will feature an exhibit ... (AACC) Annual Meeting and Clinical Lab Expo in ... 31, 2014. "We are extremely excited ... tremendous opportunity to interact with our customers and continue ...
(Date:7/29/2014)... LAKE CITY , July 29, 2014  The ... The Grand American Hotel in Salt Lake ... speakers representing some of most respected healthcare organizations in ... Health Catalyst , is an industry conference devoted to ... healthcare analytics,  an essential element of both accountable care ...
Breaking Medicine Technology:Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
(Date:7/29/2014)... Daily Gossip reveals in its Leaky Gut Cure ... and functional medicine practitioner, who spent years looking for a ... suffered from leaky gut, too, so this is what determined ... treatment. , Karen Brimeyer decided to share her story, ... the world. The author of the Leaky Gut Cure program ...
(Date:7/29/2014)... New York (PRWEB) July 29, 2014 ... protecting the rights of victims injured by defective drugs ... has been filed by plaintiffs in Canada who allege ... of cardiovascular events with the low testosterone injection ... on July 22, 2014 in the Ontario Superior Court ...
(Date:7/29/2014)... Daily Gossip reveals in its review that ... that will permanently eliminate all the symptoms associated to this ... will banish symptoms such as mild hearing loss, as well ... patients will be gone forever. , The method will lead ... of this program says that at the end of the ...
(Date:7/29/2014)... 2014 (HealthDay News) -- Want young children to embrace ... that,s healthy is good for them. Doing so will ... new study suggests. "Parents and caregivers who are ... better off simply serving the food without saying anything ... food actually is," said study authors Michal Maimaran, of ...
(Date:7/29/2014)... Randy Dotinga HealthDay Reporter ... When most children take on a task, various brain ... neuro-boosting activity in kids with autism, according to a ... symptoms of autism displayed even less of this "brain ... flexibility often causes difficulty when children with autism are ...
Breaking Medicine News(10 mins):Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 3
... from McGill University and the University of British Columbia ... expressions. McGill Psychology Prof. Jeffrey Mogil, UBC ... discovered that when subjected to moderate pain stimuli, mice ... humans do. Their study, published online May 9 in ...
... support program might be an appropriate Mother,s Day gift ... is a smoker, you might consider giving her a Mother,s ... live a longer, healthier life, suggests the American Lung Association. ... available 24 hours a day and offers users tools and ...
... ... concentrates and additive masterbatches for the plastics industry, announced plans today to open a ... PCC,s growing customer demand from the food packaging, medical device and supply, and pharmaceutical ... (PRWEB) ...
... KEL Attorneys is looking for ... , ... -- Kaufman, Englett & Lynd LLC is actively searching for individuals and businesses affected by ... a law suit on their behalf., , ,KEL Attorneys is looking for those businesses and individuals ...
... of heart disease doubled for nurses with high work pressures, ... high-pressure job can boost the risk of heart disease among ... studies have mainly looked at high-pressure jobs and men, but ... part in the Danish Nurse Cohort Study. The women were ...
... ... to its Board of Directors on April 26, 2010, Nalini N. Jairath, PhD, RN, ... four new members bring an impressive amount of experience and expertise to help support the ... ...
Cached Medicine News:Health News:McGill-UBC project creates mouse grimace scale to help identify pain in humans and animals 2Health News:Plastics Color Corporation Expands Into California 2Health News:Plastics Color Corporation Expands Into California 3Health News:KEL Attorneys is Assisting Victims of the Deepwater Horizon Oil Spill by Filling Legal Claims on Their Behalf 2Health News:Providence Hospital Appoints Four New Members to its Board of Directors 2Health News:Providence Hospital Appoints Four New Members to its Board of Directors 3
The Oscor PACE 101 H is an external single chamber cardiac demand pacemaker. The PACE 101 H feature an option for a atrial overdrive stimulation....
... quadripolar pacing wire design offers ... sensing in the atrium and ... wires in one lead design. ... and ventricle are color-coded for ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: